Biased GLP-1 Agonists: Researchers are exploring GLP-1 agonists with biased signalling profiles that may offer improved efficacy and tolerability
It is that metabolic therapy may matter more to breast cancer outcomes than many clinicians have assumed, and that this question is now important enough to deserve serious prospective study.
Williams told People Magazine, "I never was able to get to the weight I needed to be no matter what I did, no matter how much I trained." After she was done breastfeeding, Williams turned to telehealth company Ro for GLP-1 injections
While the results of the trial are dramatic, the fact is that before all the noise around GLP-1s, it was known that even modest weight-loss improved obesity-related conditions and that this had had no negative impact on the MedTech market, as illustrated below
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(736) amide infused at near-physiological insulinotropic hormone and glucose concentrations
Berg S et al